Top-News
Donnerstag,
14.12.2023 06:00
von
PR Newswire
| Aufrufe: 53
GenScript to Host Biotech Global Forum 2024 during 42nd Annual J.P. Morgan Healthcare Conference
Eine Wissenschaftlerin bei einer Untersuchung. (Symbolbild)
© Stas_Uvarov / iStock / Getty Images Plus / Getty Images
http://www.gettyimages.de/
PR Newswire
PISCATAWAY, N.J., Dec. 14, 2023
Conference to convene gene- and cell-therapy thought leaders from the research, industry, and capital communities as well as representatives from regulatory bodies
PISCATAWAY, N.J., Dec. 14, 2023 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, is kicking off 2024 with the GenScript Biotech Global Forum 2024, concurrent with the 42nd Annual J.P. Morgan Healthcare Conference.
As we close out 2023, the gene- and cell-therapy sector is booming worldwide, fueled by major innovations in life science and medicine and funding from global capital markets. To advance this crucial field in 2024, GenScript is convening top scientists and industry leaders from around the world at the Grand Hyatt in San Francisco on Wednesday, January 10, 2024.
Under the theme Innovations and Breakthroughs Shaping Tomorrow's Cell and Gene Therapies, presenters and attendees will discuss recent developments in research, technological breakthroughs, commercialization challenges, and regulatory trends. By providing a forum for thought leaders from around the world, the conference aims to accelerate the pursuit of cures that will help more patients.
Agenda highlights
- How CAR-T Leaders Drive GCT Commercialization
- The Latest in Next-Generation Gene Therapy
- What Lies Ahead for GCT Commercialization Amid a Funding Frenzy?
- Latest Policy and Regulatory Trends in GCT
- Tips for IND Filing of GCT Products
Registration is open now.
ARIVA.DE Börsen-Geflüster
About GenScript Biotech Corporation
GenScript Biotech Corporation (HK:1548) is the world's leading technology and service provider of life-science R&D and manufacturing. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms: the life-science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the industrial synthetic products platform, and the integrated global cell therapy platform.
GenScript Biotech was founded in New Jersey, USA in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech's business operations span over 100 countries and regions worldwide, with legal entities located in the US, Mainland & Hong Kong China, Japan, Singapore, Netherlands, Ireland, the United Kingdom, Korea, and Belgium. GenScript Biotech provides premium, convenient, and reliable services and products for more than 200,000 customers.
As of June 30, 2023, GenScript Biotech had more than 6,400 employees globally. The company owns numerous intellectual property rights, including over 240 patents, over 900 pending- patent applications, and a significant number of trade secrets.
Driven by the corporate mission of "make people and nature healthier through biotechnology,", GenScript Biotech strives to become the most trustworthy biotech company in the world. As of June 30, 2023, 85,100 peer-reviewed journal articles worldwide have cited GenScript Biotech's services and products. For more information, please visit GenScript Biotech's official website genscript.com.
Media contact:
Tim Cox — ZingPR for GenScript
tim@zingpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genscript-to-host-biotech-global-forum-2024-during-42nd-annual-jp-morgan-healthcare-conference-302015018.html
SOURCE GenScript Biotech Corporation
Werbung
Mehr Nachrichten kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
